Zimulti

Treatment for Obesity

Sanofi-aventis Acknowledges FDA Announcement of an Advisory Committee Meeting for rimonabant

Sanofi-aventis Acknowledges FDA Announcement of an Advisory Committee Meeting for rimonabant

PARIS, March 26, 2007 -- Sanofi-aventis announced today the FDA notice for its first in class CB1 receptor antagonist rimonabant, now scheduled for an Endocrinologic and Metabolic Drugs Advisory Committee Meeting to be held on June 13, 2007.

The Committee will discuss the efficacy and safety of rimonabant in obesity.

Sanofi-aventis is pleased to have the opportunity to present its data on rimonabant and to exchange with experts.

Source: sanofi-aventis

Posted: March 2007

Related Articles

Zimulti (rimonabant) FDA Approval History

View comments

Hide
(web5)